Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Investor Brand Network - Thu Mar 5, 2:40PM CST
  • Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages.
  • Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action.
  • HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis.

Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix (NASDAQ: SNGX) exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact.

Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. In drug development, platform technology is a foundational technology or system that serves as a base for the development of multiple products, solutions or…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).